Diagnostic kit for detecting immunogenic response and method of screening
AssigneeNovozymes A/S
InventorsErwin Ludo Roggen, Nina Teeres Nilsson, Steffen Ernst, Shamkant Anant Patkar, Esben Peter Friis
Life of this patent
Estimating the term…
Abstract
The present invention relates to a kit for predicting binding of specific antibodies to potential immunogens. The kit comprises antigenic peptide sequences having less than 26 amino acids, said antigenic peptide sequences being capable of binding antibodies specific for structural epitopes contained on potential immunogens. The antigenic peptide sequences are immobilized on a solid support.
Claims47
A kit for predicting binding of a specific antibody to at least one potential immunogen, comprising
- a) at least one antigenic peptide sequence comprising less than 26 amino acids wherein said antigenic peptide sequence corresponds to a structural epitope comprised in the at least one potential immunogen and the antigenic peptide sequence is capable of binding at least one antibody specific for the structural epitope comprised in the said potential immunogen, and
- b) solid support suitable for immobilizing the at least one antigenic peptide sequence.
The kit of any of the preceding claims, wherein the first contiguous linear sequence and the second contiguous linear sequence constitutes the structural epitope.
The kit of any of the preceding claims, wherein the at least one specific antibody, when present in excess with respect to the potential immunogen, will not bind to another antigen unless this antigen is present at a concentration which is 1000 fold higher than the potential immunogen.
The kit of any of the preceding claims, wherein the at least one antigenic peptide sequence has at least a 10 fold stronger affinity per microgram antigenic peptide towards at least one specific antibody in full blood or serum from an animal or human immunized with the full immunogen, than towards a non-specific antibody provided that the concentration of the specific antibody and the non-specific antibody is the same.
The kit of any of the preceding claims, wherein the at least one antigenic peptide sequence has at least a 10 fold stronger affinity per microgram antigenic peptide towards at least one specific antibody in purified serum from an animal or human immunized with the full immunogen than towards a non-specific antibody provided that the concentration of the specific antibody and the non-specific antibody is the same, and wherein at least 50% of the specific antibodies present in the purified serum belongs to the same class of antibodies.
The kit of any of the preceding claims, wherein the at least one antigenic peptide sequence has at least a 10 fold stronger affinity per microgram antigenic peptide towards at least one specific antibody in purified serum from an animal or human immunized with the full immunogen, than towards a non-specific antibody provided that the concentration of the specific antibody and the non-specific antibody is the same, and wherein at least 90% of the specific antibodies present in the purified serum binds to the at least one antigenic peptide sequence.
The kit of any of the preceding claims, wherein the at least one antigenic peptide is obtained by screening a random peptide library with antibodies raised against an immunogen of interest and determining the amino acid sequence of peptides binding to an antibody or the DNA sequence encoding the peptides and producing said peptides.
The kit of any of the preceding claims, wherein the at least one antigenic peptide is obtained by
- a) screening a random peptide library with antibodies raised against an immunogen of interest,
- b) determining the amino acid sequence of peptides binding to an antibody or the DNA sequences encoding the peptides,
- c) using the peptides or DNA sequences to identify at least one structural epitope pattern on the immunogen and
- d) producing antigenic peptides corresponding to structural epitopes on the immunogen.
The kit of any of the preceding claims, wherein the at least one antigenic peptide is identified by structural epitope mapping.
The kit of any of the preceding claims, wherein the potential immunogen is an allergen.
The kit of any of the preceding claims, comprising at least two different antigenic peptide sequences.
The kit of any of the preceding claims, comprising at least 10 different antigenic peptide sequences.
The diagnostic kit of any of the preceding claims, comprising at least 100 different antigenic peptide sequences.
A vaccine comprising at least one antigenic peptide sequence corresponding to a structural epitope comprised in at least one potential immunogen and said antigenic peptide sequence being capable of binding at least one antibody specific for the structural epitope comprised in the potential immunogen.
A method for the preparation of a vaccine comprising adding to a liquid medium at least one antigenic peptide sequence, corresponding to a structural epitope comprised in at least one potential immunogen and said antigenic peptide sequence being capable of binding at least one antibody specific for the structural epitope comprised in the potential immunogen.
A use of at least one antigenic peptide sequence, corresponding to a structural epitope comprised in at least one potential immunogen and said antigenic peptide sequence being capable of binding at least one antibody specific for the structural epitope comprised in the potential immunogen, for the preparation of a vaccine
Dependencies are inferred from the claim text.